Nektar Therapeutics (NKTR) Cost of Revenue (2010 - 2026)

Nektar Therapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 55.38% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $18.0 million, a 69.41% decrease from a year earlier, with the FY2024 full-year figure at $42.0 million, up 13.49% from the prior year.
• Cost of Revenue declined to $7.7 million in Q1 2026 per NKTR's latest filing, from $10.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $19.3 million in Q4 2024 and bottomed at $5.0 million in Q3 2022.
• The 5-year median for Cost of Revenue is $10.3 million (2025), against an average of $9.8 million.
• Across the five-year window, Cost of Revenue jumped 150.02% in 2023 and slumped 55.38% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $6.2 million in 2022, then soared by 69.47% to $10.6 million in 2023, then jumped by 83.07% to $19.3 million in 2024, then slumped by 46.75% to $10.3 million in 2025, then retreated by 25.2% to $7.7 million in 2026.
• Per Business Quant, the three latest NKTR Cost of Revenue figures stand at $7.7 million (Q1 2026), $10.3 million (Q3 2025), and $17.3 million (Q1 2025).